Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow.
Portfolio Pulse from
Applied Therapeutics' stock has plummeted by 73% following the FDA's decision not to approve its drug for treating a rare disease. This regulatory setback has significantly impacted the company's market value.
November 29, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Applied Therapeutics' stock dropped 73% due to the FDA's refusal to approve its drug for a rare disease, severely affecting its market position.
The FDA's decision not to approve the drug is a critical regulatory setback for Applied Therapeutics, leading to a massive 73% drop in its stock price. This indicates a loss of investor confidence and potential financial challenges ahead.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100